Evidence map›Paper›PMID 41958363›Full record

Trial reportCancer medicine2026

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Ruben Mesa, Jeanne M Palmer, Francesca Palandri, Lucia Masarova, Claire N Harrison, Flora Mazerolle, Manal M'hari, Tom Liu, Shiyuan Zhang, Anna Cardellino and 5 more

3 registry-linked trialsAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969838 phase3completednot on this map

A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

TypeinterventionalSponsorSierra Oncology LLC - a GSK companyRan2013 to 2019Enrolled432ConditionsPrimary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia MyelofibrosisArmsMomelotinib, Ruxolitinib, Placebo to match momelotinib, Placebo to match ruxolitinib
NCT02101268 phase3completednot on this map

A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib

TypeinterventionalSponsorSierra Oncology LLC - a GSK companyRan2014 to 2019Enrolled156ConditionsPrimary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)ArmsMomelotinib, Best Available Therapy (BAT)
NCT04173494 phase3completednot on this map

A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy

TypeinterventionalSponsorSierra Oncology LLC - a GSK companyRan2020 to 2022Enrolled195ConditionsPrimary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia MyelofibrosisArmsMomelotinib, Placebo to match danazol, Danazol, Placebo to match momelotinib
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ruben MesaAtrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, USA.ORCID https://orcid.org/0000-0001-5880-7972
Jeanne M PalmerMayo Clinic, Phoenix, Arizona, USA.
Francesca PalandriIRCCS Azienda Ospedaliero- Universitaria di Bologna, Istituto di Ematologia, S. Orsola-Malpighi, Bologna, Italy.ORCID https://orcid.org/0000-0001-8367-5668
Lucia MasarovaThe University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Claire N HarrisonGuy's and St Thomas' NHS Foundation Trust, London, UK.
Flora MazerolleModus Outcomes, a THREAD company, Lyon, France.
Manal M'hariModus Outcomes, a THREAD company, Lyon, France.
Tom LiuGSK, Collegeville, Pennsylvania, USA.
Shiyuan ZhangGSK, Collegeville, Pennsylvania, USA.
Anna CardellinoGSK, Collegeville, Pennsylvania, USA.
Zhaohui WangGSK, Collegeville, Pennsylvania, USA.
Catherine E EllisGSK, Collegeville, Pennsylvania, USA.
Dwaipayan PatnaikGSK, Baar, Switzerland.
Antoine RegnaultModus Outcomes, a THREAD company, Lyon, France.
Thomas W LeBlancDuke University School of Medicine, Durham, North Carolina, USA.

Funding

GSK
6 · The paper itself

Abstract

backgroundQuality of life and symptom burden of patients with myelofibrosis are well recognized and compounded in those with anemia; however, the effects of transfusion burden or anemia severity on quality of life have not been comprehensively characterized. This post hoc descriptive analysis explored the association between transfusion status or hemoglobin improvement and patient-reported outcomes (PROs).

methodsThe analysis used pooled populations across treatment arms from 3 clinical trials (SIMPLIFY-1, SIMPLIFY-2, MOMENTUM); sample sizes for each PRO measure were dependent on the trials in which they were administered.

resultsAt both baseline and week 24, transfusion independence was associated with umerically greater mean SF-36v2 and EORTC QLQ-C30 scores than transfusion dependence; in the subgroup that was transfusion dependent at baseline, those who achieved transfusion independence at week 24 had greater PRO improvements than those who remained reliant on transfusions. Regardless of transfusion status, patients who achieved a hemoglobin improvement ≥ 1, ≥ 1.5, or ≥ 2 g/dL from baseline also had clinically meaningful improvements in quality of life (assessed via mean EQ-5D-5L or SF-36v2 scores) and symptoms (assessed via PGIC or MPN-SAF/MFSAF Total Symptom Score) at week 24 compared with those who did not.

conclusionsCollectively, these results provide preliminary insights into the associations of transfusion status and anemia severity with quality of life in myelofibrosis; as current PRO measures do not directly evaluate the relationship between symptoms such as fatigue and anemia, development of new measures to more comprehensively capture the patient experience for those with anemia in myelofibrosis may be warranted.

trial registrationNCT01969838, NCT02101268, NCT04173494.

Indexed as

AnemiaBlood TransfusionHemoglobinsPatient Reported Outcome MeasuresPrimary MyelofibrosisAgedFemaleHumansMaleMiddle AgedQuality of LifeTreatment OutcomeHemoglobinsanemiahealth‐related quality of lifehemoglobinmyelofibrosispatient‐reported outcomessymptoms

Identifiers

PMID41958363
PMCPMC13066907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.